stockrowPulmatrix, Inc.
PULM Healthcare Biotechnology
Pulmatrix, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $7.8 million, up 6.96% from fiscal 2023.
- Revenue
- −99.9%
- EPS
- +31.0%
- Free cash flow
- +41.3%
Quarter to June 2026, against a year earlier
Follow PULM
Alert me
Pulmatrix, Inc. (PULM) EV/Sales
As of 6 November 2026, Pulmatrix, Inc. (PULM) trades at a EV/Sales of 0.8×. Over the past ten years it has ranged from −6.7× (September 2022) to 92.5× (February 2017); the current reading is higher than 48% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | 2.6× | — |
| FY2023 | −1.1× | — |
| FY2022 | −2.8× | — |
| FY2021 | −5.0× | — |
| FY2020 | 0.5× | — |
| FY2019 | −0.6× | — |
| FY2018 | 17.5× | (53.29%) |
| FY2017 | 37.5× | 197.58% |
| FY2016 | 12.6× | (30.77%) |
| FY2015 | 18.2× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2024 | 2.6× | 1,810.58% |
| Sep 2024 | 0.1× | — |
| Jun 2024 | −0.2× | — |
| Mar 2024 | −0.5× | — |
| 29 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CANF Can-Fite Biopharma Ltd compare | −8.7× |
| SNTI Senti Biosciences, Inc. compare | −1.1× |
| RVPH Reviva Pharmaceuticals Holdings, Inc. compare | n/m |
| ACXP Acurx Pharmaceuticals, Inc. compare | n/m |
| PULM Pulmatrix, Inc. | 0.8× |
| CNSY Cerenome, Inc. compare | 1.5× |
| IMNN Imunon, Inc. compare | 6.2× |
| PCSA Heatwurx Inc. compare | 49.5× |
| CDIO Cardio Diagnostics Holdings, Inc. compare | 61.5× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)